INTRODUCTION
============

Thyroid gland produces tetra-iodothyronine (T~4~ or thyroxine) and tri-iodothyronine (T~3~). In the human fetus, the synthesis of these hormones starts from 17 to 19th weeks of gestation (wg), therefore it is well accepted that before this period, the circulating T~3~/T~4~ in the fetus depends on the maternal levels of these hormones ([@B51]). Thus, an altered function of the thyroid gland at the maternal side could prejudice physiological levels of T~3~/T~4~ at the fetal circulation, and impair fetal growth and development. Worldwide studies indicate that \~10% of women may have hypothyroidism in their childbearing age ([@B41]; [@B30]; [@B44]). It has been also described that \~35 or \~3% of women with an apparent normal pregnancy have clinical hypothyroidism or exhibit maternal hypothyroxemia (low level of free T~4~), respectively ([@B41]), both maternal conditions associated with several alterations in the fetus development ([@B49]). Nevertheless, isolated maternal hypothyroxemia (IMH), a pathological condition manifested during pregnancy ([@B55]), have been associated with occurrence of gestational diabetes (GD; [@B46]), pre-eclampsia ([@B58]), or intrauterine growth restriction, IUGR; [@B10]). Moreover, pregnant women with IMH have higher risk (fourfold) to develop insulin resistance and GD ([@B29]; [@B67]). In fact, reduced T~4~ level in the maternal circulation is associated with an increase in the incidence of GD pregnancies ([@B46]; [@B67]) and with altered development of the central nervous system in children from pregnancies affected by these diseases ([@B60]; [@B9]). In addition, an incidence as high as \~70% of women coursing with pregnancies affected with GD exhibit IMH ([@B46]).

Gestational diabetes (GD) is associated with higher synthesis and release of vasodilators such as nitric oxide (NO) in the human fetal endothelium from GD (described as altered endothelial function) ([@B15]; [@B23]; [@B71]; [@B57]). In addition, thyroid hormones are also involved in NO synthesis and release ([@B42]; [@B20]), but the potential contribution of reduced circulating T~4~ on deregulation of fetal endothelial function seen in GD pregnancies is unclear. We here analyze the available information regarding the potential relationship between maternal and fetal thyroid hormones with the occurrence of endothelial dysfunction in GD. We propose that the low maternal levels of T~4~ seen in GD may be compensated by higher placental availability of thyroid hormones via elevation in the activity of placental thyroid hormone transport and metabolism.

OVERVIEW OF SYNTHESIS AND RELEASE OF THYROID HORMONES
=====================================================

The thyroid hormones 3,5,3′,5′-tetraiodothyronine (T~4~ or thyroxine) and 3,5,3′-triiodothyronine (T~3~) are synthesized in the thyroid gland and is regulated by hypothalamus/pituitary/thyroid axis by a negative feedback. In this regulatory axis, hypothalamus releases thyrotropin releasing hormone (TRH), which interacts with TRH receptors in thyrotropin cells in the pituitary gland to release thyroid stimulating hormone (TSH). In turn, TSH is the main regulator of the release of thyroid hormones leading to TSH receptor (TSHr) activation and increased iodo (iodide) uptake in the thyroid gland ([@B66]).

Iodide intracellular uptake is mediated by cotransport with sodium (Na^+^/I^-^) in the basal membrane of follicular cells in the thyroid gland. In these cells, iodides are oxidized by thyroid peroxidase (TPO) in the presence of hydrogen peroxide. Iodine (oxidized iodine) binds to thyroxine residues belong to the tiroglobulins (Tg), then tyroxine residues can be mono (MIT), di (DIT), tri (T~3~), or tetra-iodinated (T~4~) ([@B65]; [@B54]). The release of thyroid hormones through the basolateral membrane in thyroid gland follicular cells requires endocytosis of iodinated Tg at the apical side of these cells. The Tg is then incorporated into phagolysosomes and digested by proteolytic proteins, with MIT and DIT being re-uptaked into Tg; however, T3 and T4 are released toward circulation ([@B54]). T~4~ is the main thyroid hormone released by thyroid gland follicular cells (\~40-fold compared with T~3~) and is almost all (99.97%) bound to thyroxine binding globulin (TBG), albumin and pre-albumin in the circulation. In addition, free T~3~ accounts for \~0.3% and the rest is bound to TBG and albumin.

Free T~3~ is the hormone with biological activity and is the active form of thyroid hormones. It is derived from 5′-deiodination of free T~4~ via iodothyronine deiodinases located in the target tissues ([@B65]; [@B54]; [@B59]; [@B4]). Deiodinases are grouped in three subtypes: I, II, and III (or D1, D2, and D3, respectively), all of which are involved in the regulation of T~3~ activity ([@B4]; [@B13]). For instance, D2 is specific to generate T~3~ from T~4~; however, D3 generates DIT from T~3~, and reverse T~3~ (rT~3~, inactive form of T~3~) from T~4~ ([@B31]). D1 has been reported as an enzyme that is much less active compared with the other forms ([@B4]; [@B16]; [@B13]).

VASCULAR EFFECTS OF THYROID HORMONES
====================================

Thyroid hormones reduce peripheral vascular resistance by promoting relaxation in human and murine vascular smooth-muscle cells ([@B32]; [@B45]; [@B47]), and improve vascular reactivity by endothelium-dependent and -independent mechanisms ([@B42]; [@B20]). In rat, T~4~ released from the mesenteric arteries increases vasorelaxation when administrated at supraphysiological concentrations ([@B72]). Moreover, T~3~ and T~4~ improve fibroblast growth factor-2 (FGF-2) expression, a recognized proangiogenic factor, in cultures of ECV304 cells ([@B14]). Interestingly, human umbilical vein endothelial cells (HUVEC) exposed to high T~3~ levels exhibit high expression of endothelin-1 (vasoconstrictor) and fibronectin (profibrotic molecule), suggesting that pathological conditions such as hyperthyroidism could be associated with vasoconstriction ([@B3]; [@B17]).

In addition, there is evidence that vasoconstriction associated with high levels of thyroid hormones may result from a non-genomic action, which seems mediated by αvβ3 integrin as reported in HUVEC ([@B35]). In this regard, αvβ3 integrin is a membrane protein that should active the phosphatidylinositol 3 kinase and protein kinase B/Akt (PI3K/Akt) pathway in this cell type ([@B27]; [@B35]). Nevertheless, in another study HUVEC and bovine aortic endothelial cells (BAEC) seems to respond to T~3~ by increasing the phosphorylation of serine^1177^ (Ser^1177^; Ser^1177^-eNOS) at the endothelial nitric oxide synthase isotype (eNOS) in a time- and concentration-dependent manner ([@B27]). Similar results were seen in vascular smooth-muscle cells from rat thoracic aortae where T~3~ increases Ser^1177^-eNOS via PI3K/Akt pathway inducing eNOS, inducible (iNOS) and neuronal (nNOS) NOS expression. Thus, it is likely that T~3~ increases NOS expression via a genomic and a non-genomic (i.e., via αvβ3 integrin) action ([@B8]). Therefore, the thyroid hormone concentration is a determinant factor involved in the modulation of vascular function (**Figure [1](#F1){ref-type="fig"}**). However, there is not information addressing thyroid hormone effects on the human feto-placental vasculature.

![**Thyroids hormones effects on endothelial cells**. T~4~ (Tyrosine) is metabolized by deiodinase 2 (D~2~) to T~3~ (triiodothyronine) of manner extra and intracellular. T~3~ and T~4~ (Tyrosine) could activates αvβ3 integrin receptor which initiate a signaling that involve PI3K, Akt and eNOS, generating nitric oxide (NO) as vasodilator. But, also T3 and T4 are uptake by thyroid hormones transporters (THT). T3 bind to DNA and activate transcriptional activity for endothelin-1 and fibronectin which are associated with vasoconstriction.](fphar-05-00136-g001){#F1}

HUMAN THYROID HORMONES IN PREGNANCY
===================================

Human fetal thyroid hormones are secreted from the 17 to 19 wg, indicating that the fetus requires thyroid hormones delivery from the mother during the first and beginning of the second trimester of pregnancy ([@B51]). Pregnant women have TSH and free T~4~ levels that are normal and comparable to those in non-pregnant women; however, in the first trimester of pregnancy, there is an increase in the maternal free T~4~ level most likely in response to chorionic gonadotropin hormone (hCG; [@B19]; [@B51]). It has been shown that increased hCG level leads to reduced hypothalamus/pituitary/thyroid axis activity, but improved thyroid hormones delivery to the fetus in the first trimester of pregnancy ([@B19]; [@B51]; [@B11]). In this period, the concentration of free T~4~ in the fetal circulation corresponds to a third of the level found in the maternal circulation ([@B11]). This phenomenon results from a reduced concentration of the TBG binding protein in the fetal circulation, which leads to a free T~4~ concentration enough to exert its biological effects in embryonic tissues ([@B31]; [@B11]). In the second trimester of pregnancy, free T~4~ levels in the fetal circulation corresponds to about half of the concentration detected in the maternal circulation ([@B31]; [@B11]). Therefore, it seems clear that thyroid hormone levels are regulated by the placenta tissue ([@B7]). Thus, a role of this organ is crucial in the delivery of T~4~ to the fetus.

THYROID HORMONES METABOLISM IN THE HUMAN PLACENTA
=================================================

In addition to the paracrine effect of hCG on the hypothalamus/pituitary/thyroid axis, the human placenta regulates directly the thyroid hormone concentration in the fetal circulation by modulation of thyroid hormone transporters (THT), and by thyroid hormones metabolism mediated by deiodinases ([@B7]). THT are located at the apical and basolateral membranes of the cytotrophoblasts, syncytiotrophoblast and microvascular endothelial cells ([@B28]). There are several THT, including monocarboxylate transporters (MCT), where MCT8 and MCT10 are the main forms. Moreover, a role has been reported for [L]{.smallcaps}-amino acid transporters (LAT) and organic anion transporter polypeptides system (OATPs), which operates with less selectivity for T~4~ ([@B28]). Also in the human placenta MCT8 ([@B48]), MCT10, LAT1, LAT2 ([@B22]), OATP1A2 and OATP4A1 ([@B26]; [@B25]) have been identified, but no studies addressing the role of these membrane transporters in any pathology of pregnancy have been documented. Moreover, D2 (located at the endoplasmatic reticulum) and D3 (located at the plasma membrane with a cytoplasmic active site; [@B33]; [@B64]; [@B12]) have been identified. D2 and D3 are referred as major factors controlling transplacental transport of T~4~ to the fetus ([@B40]). Interestingly, D2 and D3 expression is up regulated by T~3~ ([@B12]). In addition, since changes in the level of T~3~/T~4~ cause altered THT expression ([@B40]), modulation of D2/D3 and THT expression by T~3~/T~4~ could be a phenomenon serving as a defense mechanism for the fetus in pregnancies where the mother courses with hypothyroxemia.

ISOLATED MATERNAL HYPOTHYROXEMIA AND CLINICAL HYPOTHYROIDISM
============================================================

The pathologies associated with low levels of free T~4~ correspond to IMH and clinical hypothyroidism. IMH (1--2% of normal pregnancies) is characterized by low free T~4~ (\<10th percentile in normal range), but normal TSH level. Instead, clinical hypothyroidism characterizes by high levels of TSH, but low levels of free T~4~ ([@B9]). In another pathological condition referred as "low T~3~ syndrome," an increase in the expression of the membrane transporters MCT8 is reported, which could be a compensatory response to low levels of thyroid hormones ([@B37]). The latter seems paralleled by an increase in the D1 and D2 levels as reported in human skeletal muscle and liver ([@B50]; [@B70]). While, using a *knockout* mice model for MCT8 (*Mct8*^-/-^) an increase in the plasma free T~4~ and T~3~ levels, and D1 and D2 expression and activity in the liver was shown ([@B18]). Therefore, these results support the fact that low levels of T~4~ lead to changes in the THT and deiodinase expression and activity in target organs. However, there is no information addressing this possibility in the human placenta from pregnancies coursing with maternal hypothyroxemia.

On the other hand, minor changes such as D2 gene polymorphism (Thr92Ala) are associated with human type 2 diabetes mellitus and insulin resistance ([@B38]). In this regard, despite there is not information regarding D2 gene polymorphism in women coursing with pregnancies without a diagnosis of thyroid gland pathology, a negative correlation between free T~4~ level and metabolic markers of GD and insulin resistance (i.e., degree of glycosylated HbA~1c~, fasting insulin, and HOMA-IR) has been shown ([@B2]). Then, it is proposed that a potential relationship between low maternal free T~4~ levels and occurrence of GD and perhaps its complications including endothelial dysfunction exists.

MATERNAL T~4~ LEVEL AND GD
==========================

GD is a disease coursing with glucose intolerance first recognized or manifested during pregnancy \[[@B39]; [@B53]; [@B1]\]. This pathology accounts for \~5% of pregnant women worldwide and it is associated with high risk of fetal perinatal alterations (e.g., macrosomia, insulin resistance) and higher incidence of diseases in the adulthood (e.g., GD, obesity, dyslipidemia, hypertension, metabolic syndrome) ([@B52]; [@B43]). GD is associated with reduced maternal circulating T~4~ levels in the first trimester of pregnancy. To date, 5% of women coursing with GD pregnancies have been shown to correlate with IMH ([@B34]). In addition, free T~4~ levels are lower in women with GD pregnancy compared with women with normal pregnancies ([@B69]) and a reduced free T~4~ level is shown in 70% of patients with GD pregnancies ([@B46]). Therefore, maternal hypothyroxemia could be associated with GD.

Other pathologies associated with low levels of free T~4~, such as clinical hypothyroidism (i.e., low free T~4~ and high TSH levels), also have been associated with GD. Indeed, 6--15% of GD pregnancies are associated with hypothyroidism ([@B69]; [@B67]; [@B63]). Moreover, if pregnant women have hypothyroidism, they have 4.3-fold higher risk for developing GD ([@B29]). There are no publications addressing the T~4~ plasma levels at the fetal circulation in a pregnancy coursing with GD. However, since GD courses with endothelial dysfunction ([@B15]; [@B71]; [@B23], [@B24]; [@B57]) and thyroid hormones modulate endothelial function ([@B42]; [@B20]), it is likely that a low free T~4~ level at the maternal circulation eventually could result in altered endothelial function in GD pregnancies.

GD AND ENDOTHELIAL DYSFUNCTION
==============================

One of the main alterations detected in GD pregnancies is the associated endothelial dysfunction of the fetoplacental circulation ([@B15]; [@B23], [@B24]; [@B71]; [@B57]). Since the vasculature in the human placenta lacks innervation ([@B36]), several local metabolic mechanisms, such as synthesis and release of vasoactive molecules (e.g., NO, adenosine) ([@B68]; [@B23], [@B24]; [@B61]) or release of nanovesicles (e.g., exosomes), most likely mediating autocrine and/or paracrine modulation of vasculature ([@B56]), could lead to acute and rapid modulation of vascular tone in this vascular bed ([@B23], [@B24]; [@B6]).

Arteries and veins in the human placenta from pregnancies with GD exhibit increased NO synthesis ([@B21]). Furthermore, similar results were early reported in primary cultures of HUVEC from pregnant women diagnosed with GD ([@B62]). Therefore, it has been proposed that vascular dysfunction in GD could result from a functional dissociation between NO synthesis and its bioavailability in the human placental circulation ([@B23], [@B24]; [@B61]). Even when endothelial dysfunction, referred to as an alteration of NO synthesis and the uptake of cationic amino acid [L]{.smallcaps}-arginine (i.e., [L]{.smallcaps}-arginine/NO pathway), is associated with GD, a clear mechanism behind these effects of GD is still unavailable ([@B24]).

HUMAN PLACENTA ENDOTHELIAL FUNCTION AND T4 IN GD: A HYPOTHESIS TO BE TESTED
===========================================================================

In normal pregnancies maternal free T~4~ is taken up by THT by the syncytiotrophoblast, where it is metabolized by D2 and D3 to be converted into T~3~ or rT~3~, respectively. T~4~ is then released via THT at the basolateral membrane of the syncytiotrophoblast into the intervillous space from where it is taken up by the microvascular endothelial cells via THT. In these cells a fraction of T~4~ is metabolized again to produce T~3~ and rT~3~ via D2 and D3, respectively (**Figure [2](#F2){ref-type="fig"}**). As a result of this process, T~4~ and T~3~ are released into the fetal blood. However, currently there is no information regarding transport of thyroid hormones across the human placenta in GD pregnancies. We propose that low levels of T~4~, lead to an increase in the number and activity of THT membrane transporters available at the plasma membrane of the human placental endothelial cells, and reduced deiodinase expression and activity, in order to supply T~4~ necessities associated with fetal development in GD. These changes could constitute a mechanism by which the endothelium from the human placenta intends to maintain normal intracellular and circulating levels of T~4~ in the fetus. The latter would be potentially reached by a greater delivery of maternal T~4~ to the fetal blood.

![**Potential thyroid hormones transplacental transport in gestational diabetes**. In cells from normal pregnancies (*Normal*) T3 and T4 in the maternal blood are transported to the fetal blood by thyroid hormone transporters (THT) through the microvascular endothelium (*Endothelium*). T3 and T4 are metabolized by deiodinases 2 (D2, forming T3) and 3 (D3, forming reverse T3 9 \[T3 from T4 and diiodothyronine (DIT) from T3)\], thus leading to modulation of these hormones delivery to the fetal blood. As hypothesis, in *Gestational diabetes* the mother courses with reduced T3 and T4 levels (red arrows). There is an increase THT and reduced D2/D3 activity, thus compensating T4 level in the fetal blood.](fphar-05-00136-g002){#F2}

FINAL COMMENTS AND CONCLUSION
=============================

Based on what was described in this review, our central research questions are: (1) is a low level of free T~4~ in the maternal circulation associated with GD? (2) is GD a disease associated with increased placental THT, but reduced deiodinase expression and activity? and (3) would the potential changes caused by reduced free T~4~ level in the maternal circulation and altered THT and deiodinases in the placenta in GD lead to placental endothelial dysfunction? Furthermore, nothing is known regarding the feto-placental vascular function/dysfunction in pregnancies where the mother courses with hypothyroxemia. Despite many benefits for using human placental tissue after birth, we acknowledge that information behind cellular mechanisms and adaptative response occurred at the beginning of pregnancy is difficult to extrapolate; however, it offers a good approximation for studying consequences of human pathologies. Potential more complex models, might include analysis of placentas collected from animal deficient in leptin receptor (*db*/*+*), since they develop GD during pregnancy ([@B5]), offering a model that may to understand molecular mechanisms of THT and deiodinases in first trimester of pregnancy. Moreover, a therapeutical approach of pregnant women coursing with hypothyroxemia targeted to improve free T~4~ circulating levels will likely reduce the risk of developing GD and the deleterious consequences of this disease in the feto-placental endothelial function. We also speculate that a normalization of free T~4~ levels in the first trimester of pregnancy could reduce the risk to face GD-associated complication.
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